Quidel Corporation Q3 2025 Earnings Recap

QDEL Q3 2025 November 6, 2025

Get alerts when QDEL reports next quarter

QuidelOrtho reported solid Q3 2025 results, showcasing organic sales growth of 5% and an adjusted EBITDA margin of 25%, reflecting strong performance across its diversified diagnostics portfolio.

Earnings Per Share Beat

$0.80 vs $0.51 est.

+56.9% surprise

Revenue Miss

699900000 vs 700234860 est.

-0.0% surprise

Market Reaction

1-Day -22.32%

5-Day -20.02%

30-Day -3.25%

See QDEL alongside your other holdings

Add to your portfolio — free

Key Takeaways

Organic sales growth of 5%, excluding COVID and the U.S. donor screening business, driven by strong demand in labs, immunohematology, and point-of-care sectors.
Adjusted EBITDA increased to $177 million, with a margin improvement of 180 basis points year-over-year.
Latin America led growth outside the U.S. with a 21% increase, while overall international revenue demonstrated strong momentum.
Successful FDA clearance of the new VITROS high-sensitivity troponin assay, enhancing the cardiac testing portfolio and potential for reduced hospital admissions.
Ongoing cost optimization initiatives have resulted in over $140 million in savings, setting the stage for sustainable mid- to high-20s EBITDA margins.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit QDEL on AllInvestView.

Next Q1 2026